Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    November 2018
  1. DUTTO L, Ahmad A, Urbanova K, Wagner C, et al
    Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.
    Br J Cancer. 2018 Nov 27. pii: 10.1038/s41416-018-0316.
    PubMed     Text format     Abstract available


  2. SCHMIDT L, Moller M, Haldrup C, Strand SH, et al
    Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.
    Br J Cancer. 2018 Nov 19. pii: 10.1038/s41416-018-0321.
    PubMed     Text format     Abstract available


  3. PREISSER F, Mazzone E, Nazzani S, Marchioni M, et al
    North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.
    Br J Cancer. 2018 Nov 14. pii: 10.1038/s41416-018-0323.
    PubMed     Text format     Abstract available


    October 2018
  4. AL-SAFFAR NMS, Troy H, Wong Te Fong AC, Paravati R, et al
    Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0242.
    PubMed     Text format     Abstract available


  5. TEO MY, Scher HI
    Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0239.
    PubMed     Text format     Abstract available


  6. PELLACANI D, Droop AP, Frame FM, Simms MS, et al
    Phenotype-independent DNA methylation changes in prostate cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0236.
    PubMed     Text format     Abstract available


    August 2018
  7. ROMERO-LAORDEN N, Lozano R, Jayaram A, Lopez-Campos F, et al
    Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0123.
    PubMed     Text format     Abstract available


    July 2018
  8. DAL MASO L, Zucchetto A, Stocco C, Serraino D, et al
    Comment on 'Anthropometric measurements and survival after prostate cancer diagnosis'.
    Br J Cancer. 2018 Jul 31. pii: 10.1038/s41416-018-0161.
    PubMed     Text format    


  9. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Reply to 'Comment on 'Anthropometric measurements and survival after prostate cancer diagnosis".
    Br J Cancer. 2018 Jul 31. pii: 10.1038/s41416-018-0213.
    PubMed     Text format    


  10. KALLIO HML, Hieta R, Latonen L, Brofeldt A, et al
    Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0172.
    PubMed     Text format     Abstract available


    June 2018
  11. HIRATA H, Hinoda Y, Shahryari V, Deng G, et al
    Correction: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells.
    Br J Cancer. 2018 Jun 22. pii: 10.1038/s41416-018-0146.
    PubMed     Text format     Abstract available


  12. MIJUSKOVIC M, Saunders EJ, Leongamornlert DA, Wakerell S, et al
    Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Br J Cancer. 2018 Jun 19. pii: 10.1038/s41416-018-0141.
    PubMed     Text format     Abstract available


    May 2018
  13. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Text format     Abstract available


    March 2018
  14. WALLIS CJD, Morton G, Herschorn S, Kodama RT, et al
    The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.
    Br J Cancer. 2018 Mar 29. pii: 10.1038/s41416-018-0071.
    PubMed     Text format     Abstract available


  15. MURTOLA TJ, Vihervuori VJ, Lahtela J, Talala K, et al
    Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0055.
    PubMed     Text format     Abstract available


  16. MIKROPOULOS C, Hutten Selkirk CG, Saya S, Bancroft E, et al
    Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Br J Cancer. 2018 Mar 6. pii: bjc201811. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


    February 2018
  17. BRAADLAND PR, Giskeodegard G, Sandsmark E, Bertilsson H, et al
    Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
    Br J Cancer. 2018 Feb 20. pii: bjc2017470. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  18. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2018 Feb 13. pii: bjc20186. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


  19. SAUNDERS EJ, Dadaev T, Leongamornlert DA, Al Olama AA, et al
    Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Br J Cancer. 2018 Feb 13. pii: bjc2017468. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2018
  20. LEE GT, Kwon SJ, Kim J, Kwon YS, et al
    WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages.
    Br J Cancer. 2018 Jan 30. pii: bjc2017451. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. QU S, Ci X, Xue H, Dong X, et al
    Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017474. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. MIKROPOULOS C, Selkirk CGH, Saya S, Bancroft E, et al
    Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Br J Cancer. 2018 Jan 4. pii: bjc2017429. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    December 2017
  23. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Anthropometric measurements and survival after a prostate cancer diagnosis.
    Br J Cancer. 2017 Dec 12. pii: bjc2017440. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  24. BRAVO I
    Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  25. TRIGGIANI L, Mazzola R, Magrini SM, Alongi F, et al
    Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''.
    Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  26. NOBLE AR, Maitland NJ, Berney DM, Rumsby MG, et al
    Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  27. LI P, Chen J, Kashiwagi E, Mizushima T, et al
    The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  28. HU J, Tian J, Zhu S, Sun L, et al
    Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-beta-induced epithelial mesenchymal transition through controlling Twist1 expression.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  29. HAQUE R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, et al
    Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
    Br J Cancer. 2017;117:1233-1240.
    PubMed     Text format     Abstract available


  30. LIU W, Wang X, Liu Z, Wang Y, et al
    SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway.
    Br J Cancer. 2017;117:1139-1153.
    PubMed     Text format     Abstract available


  31. BRAADLAND PR, Giskeodegard G, Sandsmark E, Bertilsson H, et al
    Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  32. ALEKSIC T, Verrill C, Bryant RJ, Han C, et al
    IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  33. PEREZ-CORNAGO A, Key TJ, Allen NE, Fensom GK, et al
    Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  34. DEMARK-WAHNEFRIED W, Rais-Bahrami S, Desmond RA, Gordetsky JB, et al
    Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    August 2017
  35. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  36. PIROVANO G, Ashton TM, Herbert KJ, Bryant RJ, et al
    TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
    Br J Cancer. 2017;117:503-512.
    PubMed     Text format     Abstract available


  37. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  38. CYLL K, Ersvaer E, Vlatkovic L, Pradhan M, et al
    Tumour heterogeneity poses a significant challenge to cancer biomarker research.
    Br J Cancer. 2017;117:367-375.
    PubMed     Text format     Abstract available


  39. DAI Y, Ren D, Yang Q, Cui Y, et al
    The TGF-beta signalling negative regulator PICK1 represses prostate cancer metastasis to bone.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  40. PAL D, Suman S, Kolluru V, Sears S, et al
    Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis.
    Br J Cancer. 2017;117:56-64.
    PubMed     Text format     Abstract available


  41. MARTIKAINEN M, Ruotsalainen J, Tuomela J, Harkonen P, et al
    Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice.
    Br J Cancer. 2017;117:51-55.
    PubMed     Text format     Abstract available


  42. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  43. GOTO Y, Kurozumi A, Arai T, Nohata N, et al
    Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    May 2017
  44. BARRY KH, Moore LE, Sampson JN, Koutros S, et al
    Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  45. TRIGGIANI L, Alongi F, Buglione M, Detti B, et al
    Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
    Br J Cancer. 2017 Apr 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  46. SIMMONS LAM, Kanthabalan A, Arya M, Briggs T, et al
    The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.
    Br J Cancer. 2017;116:1159-1165.
    PubMed     Text format     Abstract available


  47. JANSSEN A, Verkleij CP, van der Vlist A, Mathijssen RH, et al
    Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  48. LEE GT, Han CS, Kwon YS, Patel R, et al
    Intracrine androgen biosynthesis in renal cell carcinoma.
    Br J Cancer. 2017;116:937-943.
    PubMed     Text format     Abstract available


  49. MITTAL K, Donthamsetty S, Kaur R, Yang C, et al
    Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: